# reload+after+2024-01-23 02:45:46.672902
address1§3911 Sorrento Valley Boulevard
address2§Suite 110
city§San Diego
state§CA
zip§92121
country§United States
phone§858 550 7500
website§https://www.ligand.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.
fullTimeEmployees§76
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Todd C. Davis Ph.D.', 'age': 62, 'title': 'CEO & Director', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 743491, 'exercisedValue': 0, 'unexercisedValue': 2169}, {'maxAge': 1, 'name': 'Mr. Matthew E. Korenberg', 'age': 48, 'title': 'President & COO', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 760987, 'exercisedValue': 0, 'unexercisedValue': 701177}, {'maxAge': 1, 'name': 'Mr. Octavio  Espinoza', 'age': 52, 'title': 'Chief Financial Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 457192, 'exercisedValue': 0, 'unexercisedValue': 149672}, {'maxAge': 1, 'name': 'Mr. Andrew T. Reardon J.D.', 'age': 48, 'title': 'Chief Legal Officer & Secretary', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 480160, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Paul J. Hadden', 'title': 'Senior Vice President of Investments & Business Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Simon  Latimer', 'title': 'Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Todd  Pettingill', 'title': 'Director of Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Audrey  Warfield-Graham', 'title': 'Chief People Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Keith  Marschke', 'title': 'Senior Vice President of Biology & Scientific Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Vincent D. Antle', 'age': 54, 'title': 'Senior Vice President of Technical Operations & QA - Capitsol', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§5
compensationRisk§6
shareHolderRightsRisk§5
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
exDividendDate§1278028800
payoutRatio§0.0
beta§0.844
priceToSalesTrailing12Months§8.040573
currency§USD
dateShortInterest§1702598400
forwardEps§4.28
pegRatio§0.65
exchange§NGM
quoteType§EQUITY
shortName§Ligand Pharmaceuticals Incorpor
longName§Ligand Pharmaceuticals Incorporated
firstTradeDateEpochUtc§722097000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§bc587d73-d759-3a5b-ad33-06c1e22b5803
gmtOffSetMilliseconds§-18000000
targetHighPrice§144.0
targetLowPrice§90.0
targetMeanPrice§114.8
targetMedianPrice§110.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§14.402
grossMargins§0.61762
ebitdaMargins§0.20141001
trailingPegRatio§None
